Ophthalmic disease therapy developer EIR Biopharma announces IPO price of 4-5 USD per share, aiming to raise 17 million USD.

Ophthalmic disease therapy developer EIR Biopharma submitted its initial public offering (IPO) application to the U.S. Securities and Exchange Commission (SEC) on Tuesday, planning to issue 3.8 million shares of stock at a price of $4 to $5 per share, raising $17 million. The company plans to list on the NYSE's junior market and has not yet selected a trading symbol. EIR Biopharma, headquartered in San Francisco, California, is an early-stage biopharmaceutical developer focused on the treatment of ophthalmic diseases. The company imports preclinical drug candidates from academic institutions and advances them to the clinical development stage, targeting identified unmet needs areas. Its candidate products include EIR-0205, a small molecule therapy being developed for the treatment of dry age-related macular degeneration, designed to extract lipofuscin from retinal pigment epithelial cells; and EIR-1003, a peptide candidate drug that aims to mimic a liver apolipoprotein ligand, promoting optic nerve regeneration after retinal nerve damage. The company is conducting pre-study research for these two projects and plans to initiate human clinical studies starting from 2027.